The world market for cancer therapeutics is growing at a brisk double-digit
pace, with revenues surpassing $40 billion this year. This study looks at each
therapeutic approach in turn, reporting and forecasting revenues from 2002
through 2009. Market share by leading competitor in each therapy type is
estimated for the year 2004. Therapy types considered, include:
- Chemotherapy
- Hormone Therapy
- Radiation Therapy
- Immunotherapy and Biotherapy, and
- Adjunctive Therapies
The study focuses on current and emerging markets, products in development,
and trends affecting the cancer treatment market. Demographic and
epidemiological data are presented for the major cancer types, therapies in
development are reviewed by development stage and earliest possible approval
date, and profiles of the leading and significant competitors are included for
reference.
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information. For the purpose of this study Kalorama Information
conducted interviews with key industry officials, consultants, health care
providers, and government personnel. These sources were the primary basis in
gathering information specifically relating to revenue and market share data
presented in this report. Specific interviews with pharmaceutical company
representatives included marketing directors, division managers, and product
representatives.
All market data pertain to the world market at the manufacturers level.
The base year for data was 2004. Historical data was provided for the years 2002
and 2003, with forecast data provided for 2005 through 2009. Compound annual
growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009
periods for each industry segment covered. Competitive analysis is provided for
the year 2004. The forecasted market analysis for 2005-2009 was based on
probability of approval and sales of products in late stage development, product
marketing, and demographic trends.
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- What is Cancer?
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- History and Growth of the Cancer Treatment Market
- Industry Structure
- Demographics and Statistics
- Description of Cancers with Available products
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
- Alkylating Agents
- Nitrogen Mustards
- Cisplatin
- Antimetabolites
- Cytosine Arabinoside
- 5-Fluorouracil (5-FU)
- Hydroxyurea
- Mercaptopurine and Thioguanine
- Methotrexate
- Cytotoxic Antibiotics
- Actinomycin D
- Daunorubicin and Doxorubicin
- Bleomycins
- Plant Derivatives
- Etoposide and Teniposide
- Vincristine and Vinblastine
- Description of Products
- Alkalyting Agents
- Antimetabolites
- Cytotoxic Antibiotics
- Plant Derivatives
- Research and Development
- New Approvals
- Products in Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
- Corticosteroids
- Hormone Agonists and Antagonists
- Estrogens
- Androgens
- Antiestrogens
- Antiandrogens
- Gonadotropin-Releasing Hormone Analogues
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Description of Products
- Corticosteroids
- Hormone Agonists and Antagonists
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FIVE: IMMUNOTHERAPY/BIOTHERAPY
- Monoclonal Antibodies
- Interleukins/Interferons
- Vaccines
- Other Biotherapy
- Antisense Oligonucleotides
- Apoptosis
- Growth Factors
- Methylation
- P53
- Ras Protein Drugs
- Regulatory Enzymes
- Description of Products
- Monoclonal Antibodies
- Interleukins/Interferons
- Vaccines
- Other Biotherapy
- Research and Development
- Awaiting Approval
- Phase III
- Phase II
- Phase I
- Market Size and Growth
- Competitive Analysis
CHAPTER SIX: RADIATION THERAPY
- Effects of Radiation
- Radioactive Isotopes
- Description of Products
- Sodium Radiophosphate
- Sodium Radioiodine
- Radiopharmaceuticals
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER SEVEN: ADJUNCTIVE THERAPIES
- Antinauseants and Antiemetics
- Biologic Response Modifiers
- Anti-Infectives
- Narcotic Analgesics
- Antidepressants
- Description of Products
- Antinauseants and Antiemetics
- Hematopoietic Growth Factors
- Cytomodulatory Agents
- Anti-infectives
- Narcotic Analgesics
- Non-Narcotic Analgesics
- Antidepressants
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER EIGHT: ISSUES AND TRENDS
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Marketing and Distribution Trends
- Immunogenicity
- Geographical Trends
- United States
- European Union
- Japan
- Lifestyle and Social Issues
- Drug Delivery Advancements
- individualized chemotherapy
- Chemotherapy and Memory Loss
- Elderly Clinical Trial Involvement
- Thalidomide Controversy
- Early Detection and Screening
- New Application for Tobacco Plant
- Future Business Strategies
CHAPTER NINE: MARKET SUMMARY AND FORECAST
- Total Market Size and Forecast
CHAPTER TEN: CORPORATE PROFILES
- Introduction
- Amgen, Inc.
- AstraZeneca plc
- Biogen IDEC, Inc.
- Bristol-Myers Squibb Company/Oncology
- Chiron Corporation
- Eli Lilly & Company
- GE Healthcare
- Genentech, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Group
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Schering-Plough Corporation
- TAP Pharmaceutical Products, Inc.
- Theragenics Corporation
APPENDIX: COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: World Market for Cancer Therapies Revenues and Growth Rates
2002-2009
- Figure 1-1: World Cancer Therapies Market 2002-2009
CHAPTER TWO: INTRODUCTION
- Table 2-1: Viruses Associated with Cancer in Humans
- Table 2-2: Estimated and Projected World Cancer Incidence by Most Common
Types of Cancer, 2003 and 2020
- Figure 2-1: Estimated and Projected World Cancer Incidence by Most Common
Types of Cancer, 2003 and 2020
- Table 2-3: Estimated and Projected World Cancer Mortality by Most Common
Types of Cancer, 2003 and 2020
- Figure 2-2: Estimated and Projected World Cancer Mortality by Most Common
Types of Cancer, 2003 and 2020
- Table 2-4: World Population by Selected Geographical Region, 2003-2050
- Figure 2-3: World Population by Selected Geographical Region, 2003-2050
- Table 2-5: Estimated World Population by Age and Geographical Region 2003
- Figure 2-4: Estimated World Population by Age and Geographical Region,
2003
- Table 2-6: Life Expectancy at Birth by Selected Countries, 2000
- Table 2-7: United States Life Expectancy at Birth, 1990-2000, and
Projections, 2005-2010
- Figure 2-5: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2000
- Figure 2-6: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2000
- Table 2-8: Types of Leukemia, Incidence, Characteristics, Manifestations
- Table 2-9: Types of Primary Lung Cancer, Risk Factors
- Table 2-10: Classification of Non-Hodgkins Lymphomas
- Table 2-11: Malignant Conditions of the Skin
- Table 2-12: Estimated World Incidence and Mortality of Cancers with
Available Products (thousands)
- Figure 2-7: Estimated World Incidence and Mortality of Cancers with
Available Products
- Figure 2-8: Estimated U.S. Incidence and Mortality of Cancers with
Available Products
CHAPTER THREE: CHEMOTHERAPY
- Table 3-1: Currently Marketed Alkylating Agents (Brand Name , Generic
Name, Manufacturers, Uses)
- Table 3-2: Currently Marketed Antimetabolites
- Table 3-3: Currently Marketed Cytoxic Antibiotics
- Table 3-4: Currently Marketed Plant Derivatives
- Table 3-5: Newly Approved Chemotherapy Agents
- Table 3-6: Chemotherapy Drugs in the Pipeline
- Table 3-7: World Market for Chemotherapy Products in Cancer Revenues and
Growth Rates 2002-2009
- Figure 3-1: World Chemotherapy Market 2002-2009
- Table 3-8: Estimated Chemotherapy Products Sales by Cancer Type 2004
- Figure 3-2: Estimated Market Share of Chemotherapy Product Sales by Cancer
Type 2004
- Table 3-9: Estimated Chemotherapy Product Sales by Region 2004
- Figure 3-3: World Chemotherapy Market Share by Region 2004
- Table 3-10: Estimated Leading Suppliers Revenues and Shares of the
World Chemotherapy Market 2004
- Figure 3-4: Estimated Leading Suppliers Shares of the World
Chemotherapy Market 2004
- Table 3-11: Top Chemotherapy Products Estimated Sales and Market Share in
Cancer 2004
CHAPTER FOUR: HORMONE THERAPY
- Table 4-1: Currently Marketed Corticosteroids
- Table 4-2: Currently Marketed Hormone Agonists and Antagonists
- Table 4-3: Currently Marketed Aromatase Inhibitors
- Table 4-4: Currently Marketed Selective Estrogen Receptor Modulators
- Table 4-5: Cancer Hormone Therapy in Development
- Table 4-6: World Market for Hormone Therapy Products in Cancer Revenues
and Growth Rates 2002-2009
- Figure 4-1: World Hormone Therapy Market 2002-2009
- Table 4-7: Estimated Hormone Therapy Products Sales by Cancer Type 2004
- Figure 4-2: Estimated Market Share of Hormone Therapy Product Sales by
Cancer Type 2004
- Table 4-8: Estimated Hormone Therapy Product Sales by Region 2004
- Figure 4-3: World Hormone Therapy Market Share by Region 2004
- Table 4-9: Estimated Leading Suppliers Revenues and Shares of the World
Hormone Therapy Market 2004
- Figure 4-4: Estimated Leading Suppliers Shares of the World Hormone
Therapy Market 2004
- Table 4-10: Top Hormone Therapy Products Estimated Sales and Market Share
in Cancer 2004
CHAPTER FIVE: IMMUNOTHERAPY/BIOTHERAPY
- Table 5-1: Currently Marketed Monoclonal Antibodies
- Table 5-2: Currently Marketed Interleukins/Interferons
- Table 5-3: Currently Approved Cancer Vaccines
- Table 5-4: Other Biotherapy Currently Marketed for Cancer Treatment
- Table 5-5: Cancer Immunotherapy and Biotherapy Products in Development
- Table 5-6: World Market for Biotherapy and Immunotherapy Products in
Cancer Revenues and Growth Rates 2002-2009
- Figure 5-1: World Biotherapy and Immunotherapy Market 2002-2009
- Table 5-7: Estimated Biotherapy and Immunotherapy Products Sales by Cancer
Type 2004
- Figure 4-2: Estimated Market Share of Biotherapy and Immunotherapy Product
Sales by Cancer Type 2004
- Table 5-8: Estimated Immunotherapy/Biotherapy Product Sales by Region 2004
- Figure 5-3: World Immunotherapy/Biotherapy Market Share by Region 2004
- Table 5-9: Estimated Leading Suppliers Revenues and Shares of the World
Immunotherapy and Biotherapy Market 2004
- Figure 5-4: Estimated Leading Suppliers Shares of the World
Immunotherapy and Biotherapy Market 2004
- Table 5-10: Top Immunotherapy/Biotherapy Products Estimated Sales and
Market Share in Cancer 2004
CHAPTER SIX: RADIATION THERAPY
- Table 6-1: Currently Marketed Radiation Therapy Products
- Table 6-2: Cancer Radiation Therapy in Development
- Table 6-3: World Market for Radiation Therapy Products in Cancer Revenues
and Growth Rates 2002-2009
- Figure 6-1: World Radiation Therapy Market 2002-2009
- Table 6-4: Estimated Radiation Therapy Product Sales by Region 2004
- Figure 6-2: World Radiation Therapy Market Share by Region 2004
- Table 6-5: Estimated Leading Suppliers Revenues and Shares of the World
Radiation Therapy Market 2004
- Figure 6-3: Estimated Leading Suppliers Shares of the World Radiation
Therapy Market 2004
CHAPTER SEVEN: ADJUNCTIVE THERAPIES
- Table 7-1: Side-Effects Associated with Chemotherapy
- Table 7-2: Side-Effects Associated with Radiation Therapy
- Figure 7-1: Incidence of Emesis in Cancer Patients
- Table 7-3: Chemotherapy Agents and Level of Emetic Potential
- Figure 7-2: Incidence of Bone Marrow Suppression in Cancer Patients
- Table 7-4: Common Infection Sites
- Figure 7-3: Incidence of Infection in Cancer Patients
- Figure 7-4: Incidence of Pain in Cancer Patients
- Figure 7-5: Incidence of Depression in Cancer Patients
- Table 7-5: Currently Marketed Antinauseants and Antiemetics
- Table 7-6: Currently Marketed Biological Response Modifiers
- Table 7-7: Currently Marketed Antibiotics and Antivirals for Adjunctive
Cancer Therapy
- Table 7-8: Currently Marketed Antifungals for Adjunctive Cancer Therapy
- Table 7-9: Currently Marketed Narcotic Analgesics for Adjunctive Cancer
Therapy
- Table 7-10: Currently Marketed Non-Narcotic Analgesics for Adjunctive
Cancer Therapy
- Table 7-11: Currenlty Marketed Antidepressants for Adjunctive Cancer
Therapy
- Table 7-12: Adjunctive Cancer Therapies in Development
- Table 7-13: World Market for Adjunctive Therapy Products in Cancer
Revenues and Growth Rates 2002-2009
- Figure 7-6: World Adjunctive Cancer Therapy Market 2002-2009
- Table 7-14: Estimated Adjunctive Therapy Product Sales by Region 2004
- Figure 7-7: World Adjunctive Therapy Market Share by Region 2004
- Table 7-15: Estimated Leading Suppliers Revenues and Shares of the
Adjunctive Therapies Market 2004
- Figure 7-8: Estimated Leading Suppliers Shares of the World Adjunctive
Therapies Market 2004
- Table 7-16: Top Adjunctive Therapy Products Estimated Sales and Market
Share in Cancer 2004
CHAPTER EIGHT: ISSUES AND TRENDS
- Table 8-1: Cancer Detection Tests
- Table 8-2: Competitive Strategies of Biotech Companies
CHAPTER NINE: MARKET SUMMARY AND FORECAST
- Table 9-1: World Market for Cancer Therapies Revenues and Growth Rates
2002-2009
- Figure 9-1: World Cancer Therapies Market 2002-2009
- Table 9-2: World Market for Cancer Therapies by Type 2002-2009
- Figure 9-2: World Cancer Therapies Market Revenue Trend by Type of Therapy
2002-2009
- Figure 9-3: Make-Up of World Cancer Market by Type of Therapy 2004
- Figure 9-4: Make-Up of World Cancer Market by Type of Therapy 2009
